Eighty-Three Percent of Diabetes Educators Polled at the American Association of Diabetes Educators Conference Believe iglucose Would Improve Patient Outcomes
PositiveID Submitted Its 510(k) Pre-Market Notification Application for iglucose to FDA in July 2011
DELRAY BEACH, Fla., Sept. 27, 2011 (GLOBE NEWSWIRE) -- PositiveID Corporation ("PositiveID" or "Company") (OTCBB:PSID), a developer of medical technologies for diabetes management, clinical diagnostics and bio-threat detection, announced today the results of a survey of diabetes educators and healthcare professionals regarding the Company's iglucose™ wireless communication system to facilitate diabetes management. PositiveID surveyed attendees at the American Association of Diabetes Educators ("AADE") annual conference.
PositiveID's survey results showed:
- Eighty-three percent of diabetes educators believe using iglucose would improve patient outcomes.
- Eighty-two percent of diabetes educators believe using iglucose would improve patient consults.
- Seventy-six percent of diabetes educators would recommend iglucose to their patients.
For years the American Diabetes Association and U.S. Centers for Disease Control and Prevention have recommended that individuals with diabetes self-monitor and take a record of their glucose readings to their healthcare professionals. An AADE positioning statement revealed that self-monitoring is the best way for people with diabetes, as well as healthcare professionals, to assess the ongoing efficacy of all aspects of the diabetes management regimen, including medication and patient behavior. The problem is that most people do not keep consistent and accurate logbooks. iglucose eliminates the burden of keeping logbooks and empowers people with diabetes to be more engaged in the self-management of their condition.
iglucose uses mobile technology to seamlessly communicate blood glucose readings from an individual's data-capable glucometer to the iglucose diabetes management portal, where, with the user's consent, glucose readings can be shared automatically with family members, caregivers and healthcare professionals via text message, email or fax.
More than 25 million children and adults in the U.S. have diabetes, or over 8 percent of the population, according to the 2011 National Diabetes Fact Sheet. The Centers for Disease Control and Prevention predicts that nearly 30 percent of children born after the year 2000 will develop diabetes. Worldwide, the number of adults with diabetes has doubled over the last three decades to nearly 350 million and increased nearly three-fold in the U.S., according to a study published in the British journal Lancet. The lifetime risk of developing diabetes for those born in the year 2000 is 35 percent. The total cost of diagnosed diabetes in the U.S. was estimated at $174 billion in 2007.
For more information on iglucose, please visit www.iglucose.com. This product has not been cleared for sale by the U.S. Food and Drug Administration.
About PositiveID Corporation
PositiveID Corporation develops unique medical devices and molecular diagnostic systems, focused primarily on diabetes management, rapid medical testing and airborne bio-threat detection. Its wholly-owned subsidiary, MicroFluidic Systems, is focused on the development of microfluidic systems for automated preparation of and performance of biological assays. For more information on PositiveID, please visit www.PositiveIDCorp.com.
The PositiveID Corporation logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=7717
Statements about PositiveID's future expectations, including the likelihood that diabetes educators believe using iglucose would improve patient outcomes; the likelihood that diabetes educators believe using iglucose would improve patient consults and would recommend iglucose to their patients; the likelihood that iglucose eliminates the burden of keeping logbooks and empowers people with diabetes to be more engaged in the self-management of their condition; the likelihood that nearly 30 percent of children born after the year 2000 will develop diabetes; and all other statements in this press release other than historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and PositiveID's actual results could differ materially from expected results. These risks and uncertainties include the Company's ability to successfully commercialize the iglucose system; as well as certain other risks. Additional information about these and other factors that could affect the Company's business is set forth in the Company's various filings with the Securities and Exchange Commission, including those set forth in the Company's 10-K filed on March 25, 2011, and 10-Qs filed on May 13, 2011, and August 15, 2011, under the caption "Risk Factors." The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.